R&D Platform of Nucleic Acid Innovative Drugs

Time:2020-09-29

Increasepharm (HK) was established in Hong Kong in 2018. It started IUR (Industry-University-Research) cooperation with universities and major research institutes in GBA (Guangdong-Hong Kong-Macao Greater Bay) and overseas. Increasepharm (HK) takes advantage of technology on biomedicine field and talents in GBA to enhance the capacity to transform the technological achievements, building the international technology innovation center.


Increasepharm (HK) devotes to the R&D of nucleic acid innovative drugs, cooperates with HKBU (YKRH00279 drug discovery) and MUST (YKRH00021 drug discovery) and establishes a platform, expanding models of cooperation between enterprises and universities in Hong Kong and Macau. Increasepharm (HK) collaborates with HKBU (YKRH00279) by using ApDC technology to enhance the targeting and safety of the small molecule drugs. Compared with antibody-drug conjugates (ADC), nucleic acid aptamer are less immunogenic, easier to synthesize and more selectable targets. Besides, from the perspective of clinical efficacy of TCM, the cooperation with MUST (YKRH00021) designed siRNA based on natural drug RNA sequence. It provides a new idea for the design method of siRNA and contributes to the development of TCM resources. On the one hand, HKBU and MUST with advanced equipment and high-level research team. On the other hand, Increasepharm (HK) has strong professional strength in new drug R&D and the ability to transform technological achievements. The IUR between Increasepharm (HK) and HKBU and MUST generate great synergy, providing strategic cooperation to build a nucleic acid drug research and development platform. The company provides a strategic R&D platform, and the school focuses on new drug innovation research. IUR cooperation promotes the R&D of nucleic acid drugs, solves the bottleneck technology of innovative nucleic acid drugs and promotes the high-quality development of nucleic acid drug industry.

Scan the WeChat QR code